• Login
Redica Systems
  • For Pharma

    Our data generates critical pharma insights with our actionable data intelligence helping your team go from reactive to proactive.

    For MedTech

    Elevate your MedTech quality and regulatory strategies with our comprehensive intelligence solutions and unparalleled dataset.

  • Catalyst
  • About Us
    • People
    • Careers
    • Press
  • Resources

    View all Resources

    • Assessments
    • Reports
    • Webinars
    • Glossary
  • Blog
Request a Demo
Redica Systems
    • Redica Systems MedTech Intelligence
    • Redica Systems Pharma Intelligence
  • Catalyst
    • About Redica Systems
    • People
    • Careers
    • Press
  • Resources
  • Blog
Request a Demo
  • Login

Resources

FDA Sent These 7 Warning Letters for Pharma Companies | February 2017

We took a snapshot of the 7 warning letters the FDA sent to pharmaceutical companies last month. Drug manufacturing violations ranged from failing to maintain complete data (again) to failing to produce suitable water. From pharmaceuticals in Japan, Illinois, and more, here they are (starting with the most recent): Megafine Pharma, Mumbai, India – 4 violations:Failure […]

What is the Future of Outsourcing Facilities?

What is the Future of Outsourcing Facilities? PART II Policies, Enforcement, and Predictions Policies:In this section, we will address policies and guidance that the FDA has published since the end of 2013, look at enforcement activities in this area, and make some predictions for the future of this market segment. According to the FDA website,FDA […]

Outsourcing Facilities: Are They Still Worth It and Were They Ever?

The Real Story Behind Outsourcing Facilities: Are They Still Worth It and Were They Ever? PART I History and Background: The New England Compounding Center (NECC) preparation and shipment of contaminated injectable products across state lines in 2012 created a firestorm of publicity and enforcement actions. More than 750 patients in twenty states developed a fungal […]

FDA Sent These 10 Warning Letters for Pharma Companies | January 2017

We took a snapshot of the 10 warning letters the FDA sent to pharmaceutical companies last month. Drug manufacturing violations ranged from products not meeting “the definition and standard for chocolate” to sites “refusing to permit the FDA inspection” altogether. From pharmaceuticals in Italy, Pennsylvania, and more, here they are (starting with the most recent): Berkeley […]

10 Ways to Prepare for a GMP Inspection

How to Prepare for a GMP Inspection for Small and Virtual Companies Preparing for GMP inspections, particularly pre-approval inspections, can be a challenge when resources are limited and staff may have little expertise in these important activities. This becomes especially complex for start-up companies that are virtual, or essentially virtual, and rely on contract manufacturers […]

FDA Sent These 5 Warning Letters for Pharma Companies | December 2016

We took a snapshot of the 5 warning letters the FDA sent to pharmaceutical companies last month. Drug manufacturing violations ranged from failing to put expiration dates on containers to failing to put soap in the bathrooms. From pharmaceuticals in Canada, Spain, and more, here they are (starting with the most recent): Horizon Pharmaceuticals, Inc., […]

FSMA is Here. How Do You Manage 1,000 Food Suppliers?

FSMA is Here. How Do You Manage 1,000 Food Suppliers? The advent of the FSMA in the US means that everyone in your supplier network can expect an inspector to knock at some point, underlining the imperative for supplier accountability to compliance teams. Brand revenue and reputation ride on the outcome. This means effectively keeping […]

6 Changes in Regulatory and GMP Intelligence

  Changes in Regulatory and GMP Intelligence Surveillance, analysis and communication of regulatory and GMP intelligence has evolved over the past decade. The individual(s) tasked with this activity within pharma companies require broad experience in regulatory affairs and GMP compliance. The individual(s) must have sufficient historical perspective to compare and contrast new requirements with those they […]

An Alternative to GMP Quality System Auditing in the Pharma Industry

An Alternative to GMP Quality System Auditing in the Pharma Industry Executive Summary: Historically, a quality systems approach to GMP auditing has become common practice. However, this systems approach does not routinely address the essential input into the system – the data.Data integrity issues have drastically increased in the last year – and not just […]

Last 30 483s Customers Have Purchased – December 2016

We see a lot of people, all throughout the world, purchasing 483s from our FDA 483s store. For example, this month, customers from theUnited States, India, South Korea, China, and the United Kingdom purchased 483s. As a reminder, here are 5 features to look for in a 483. Here are the latest 30 483s purchased […]
« Older Entries
Newer Entries »
Company
  • About Redica Systems
  • People
  • Careers
  • Press
  • Contact Us
Catalyst
  • Redica Catalyst
  • Redica ID
  • Enrichment
  • Knowledge Graph
  • Redica Ontologies
Use Cases
  • For Pharma
  • For MedTech
  • Inspection Preparation
  • Vendor Quality
  • Regulatory Surveillance
Resources
  • Assessments
  • Reports
  • Webinars
  • Document Store
  • Blog
  • Glossary

© 2025 Redica. All Rights Reserved.

  • Privacy Policy
  • Terms of Use
  • Status